
    
      Study PCYC-1112-CA is a randomized, multicenter, open-label, phase 3 study of the Bruton's
      Tyrosine Kinase (BTK) inhibitor Ibrutinib (PCI-32765) versus Ofatumumab in patients with
      Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

      Patients randomized to the ofatumumab arm may be considered to receive next subsequent
      therapy with ibrutinib.
    
  